Inhaled antibiotics for lower respiratory tract infections: Focus on ciprofloxacin

Drugs of Today

Volumn 48, Issue 5, 2012, Pages 339-351

  Serisier, David J ^a,b,c  

^a MATER ADULT HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

ARD 1100; ARD 3150; Ciprofloxacin; Quinolone; Respiratory disorders

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ARD 3100; AZTREONAM; AZTREONAM LYSINE; BAY 41 6551; CARBENICILLIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COLOBREATH; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; LIPOQUIN; PLACEBO; PULMAQUIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BRONCHIECTASIS; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENCAPSULATION; HUMAN; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; POPULATION RESEARCH; REVIEW; RISK ASSESSMENT;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CIPROFLOXACIN; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; HUMANS; LIPOSOMES; NEBULIZERS AND VAPORIZERS; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 84861989861     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.5.1789474     Document Type: Review

References (67)

1. Solis, A., Brown, D., Hughes, J., Van Saene, H.K., Heaf, D.P. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 2003, 36(3): 189-95. (Pubitemid 37055965)
2. Li, Z., Kosorok, M., Farrell, P.M. et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293(5): 581-8. (Pubitemid 40171240)
3. Wainwright, C.E., Vidmar, S., Armstrong, D.S. et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011, 306(2): 163-71.
4. Pier, G.B., Coleman, F., Grout, M., Franklin, M., Ohman, D.E. Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Infect Immun 2001, 69(3): 1895-1901. (Pubitemid 32187652)
5. Drenkard, E., Ausubel, F.M. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002, 416(6882): 740-3. (Pubitemid 34429150)
6. Singh, P.H., Schaefer, A.L., Parsek, M.R., Moninger, T.O., Welsh, M.J., Greenberg, E.P. Quorum sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000, 407(6805): 762-4.
7. Geller, D.E., Pitlick, W.H., Nardella, P.A., Tracewell, W.G., Ramsey, B. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122(1): 219-26. (Pubitemid 34754166)
8. Mendelman, P.M., Smith, A.L., Levy, J., Weber, A., Ramsey, B., Davis, R.L. Aminoglycoside penetration, inactivation and efficiency in cystic fibrosis sputum. Am Rev Respir Dis 1985, 132(4): 761-5. (Pubitemid 16247735)
9. Lu, Q., Yang, J., Liu, Z., Gutierrez, C., Aymard, G., Rouby, J.J. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011, 184(1): 106-15.
10. Palmer, L.B., Smaldone, G.C., Chen, J.J. et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008, 36(7): 2008-13.
11. Palmer, L.B. Aerosolized antibiotics in the intensive care unit. Clin Chest Med 2011, 32(3): 559-74.
12. Niederman, M.S., Chastre, J., Corkery, K., Fink, J.B., Luyt, C.E., Garcia, M.S. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with gram-negative pneumonia. Intensive Care Med 2012, 38(2): 263-71.
13. Barker, A.F., Couch, L., Fiel, S.B. et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000, 162(2, Part 1): 481-5. (Pubitemid 30647187)
14. Wilson, C.B., Jones, P.W., O'Leary, C.J., Hansell, D.M., Cole, P.J., Wilson, R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997, 10(8): 1754-60. (Pubitemid 27368366)
15. King, P.T., Holdsworth, S.R., Freezer, N.J., Villanueva, E., Holmes, P.W. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007, 101(8): 1633-8. (Pubitemid 46930715)
16. Langton-Hewer, S.C., Smyth, A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009, (4): CD004197.
17. Hodson, M., Penketh, A.R.L., Batten, J.C. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981, 2(8256): 1137-9. (Pubitemid 11029642)
18. Wall, M.A., Terry, A.B., Eisenberg, J., McNamara, M., Cohen, R. Inhaled antibiotics in cystic fibrosis. Lancet 1983, 1(8337): 1325. (Pubitemid 13096236)
19. Stead, R.J., Hodson, M.E., Batten, J.C. Inhaled ceftazadime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987, 81(3): 272-9. (Pubitemid 17091811)
20. Kun, P., Landau, L.I., Phelan, P.D. Nebulised gentamicin in children and adolescents with cystic fibrosis. Aust Paediatr J 1984, 20: 43-5. (Pubitemid 14123235)
21. Jensen, T., Pedersen, S.S., Garne, S., Heilman, C., Hoiby, N., Koch, C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987, 19(6): 831-8. (Pubitemid 17092071)
22. Ramsey, B.W., Dorkin, H.L., Eisenberg, J.D. et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993, 328(24): 1740-45.
23. Ramsey, B.W., Pepe, M.S., Quan, J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999, 340(1): 23-30. (Pubitemid 29024680)
24. Burns, J.L., van Dalfsen, J.M., Shawar, R.M. et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999, 179(5): 1190-6. (Pubitemid 29196500)
25. Moss, R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002, 121(1): 55-63. (Pubitemid 34114228)
26. Konstan, M.W., Flume, P.A., Kappler, M. et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibr 2011, 10(1): 54-61.
27. McCoy, K.S., Quittner, A.L., Oermann, C.M., Gibson, R.L., Retsch-Bogart, G.Z., Montgomery, A.B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178(9): 921-8.
28. Retsch-Bogart, G.Z., Quittner, A.L., Gibson, R.L., Oermann, C.M., McCoy, K.S., Montgomery, A.B., Cooper, P.J. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009, 135(5): 1223-32.
29. Wainwright, C.E., Quittner, A.L., Geller, D.E. et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment and P. aeruginosa. J Cyst Fibr 2011, 10(4): 234-42.
30. Colobreathe (colistimethate sodium) EPAR Summary for the Public. European Medicines Agency. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Summary-for-the-public/human/001225/WC50012369 4.pdf. Accessed April 2, 2012.
31. Dupont, L.J., Clancy, J.P., Minic, P. et al. Evaluation of two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med [106th Int Conf Am Thorac Soc (May 14-19, New Orleans) 2010] 2010, 181(Abstract Issue): Abst 1836.
32. Insmed Incorporated provides corporate update [news release]. Insmed Incorporated, January 20, 2012. http://investor.insmed.com/releasedetail.cfm? ReleaseID=641200. Accessed February 7, 2012.
33. Geller, D.E., Flume, P.A., Staab, D., Fischer, R., Loutit, J.S., Conrad, D.J. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011, 183(11): 1510-6.
34. Trapnell, B.C., McColley, S.A., Kissner, D.G. et al. Fosfomycin/ tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Respir Crit Care Med 2012, 185(2): 171-8.
35. Oermann, C.M., Assael, B., Nakamura, C., Boas, S.R., Bresnik, M., Montgomery, A.B., Pressler, T. Aztreonam inhalation solution (AZLI) vs tobramycin inhalation solution (TIS), a 6-month comparative trial in cystic fibrosis patients with Pseudomonas aeruginosa. Pediatr Pulmonol [24th Annu North Am Cystic Fibrosis Conf (Oct 21-23, Baltimore) 2010], 2010, 45(S33): Abst 305.
36. Chono, S., Tanino, T., Seki, T., Morimoto, K. Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections. Drug Metab Pharmacokinet 2007, 22(2): 88-95.
37. Maurer, N., Fenske, D.B., Culler, P.R. Developments in liposomal drug delivery systems. Expert Opin Biol Ther 2001, 1(6): 923-47.
38. Chono, S., Tanino, T., Seki, T., Morimoto, K. Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev Indust Pharm 2008, 34(10): 1090-6.
39. Wong, J.P., Yang, H., Blasetti, K.L., Schnell, G., Conley, J., Schofield, L.N. Liposome delivery of ciprofloxacin against intracellular Francisca tularensis infection. J Control Release 2003, 92(3): 265-273. (Pubitemid 38366150)
40. Blanchard, J.D. Pulmonary drug delivery as a first response to bioterrorism. In: Respiratory Drug Delivery X. Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J. (Eds.). Davis Healthcare International: River Grove, IL., 2006: 73-82.
41. Di Ninno, V.L., Cherwonogrodzky, J.W., Wong, J.P. Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of BALB/c mice against Francisella tularensis. J Infect Dis 1993, 168(3): 793-4. (Pubitemid 23254316)
42. Conley, J., Yang, H., Wilson, T., Blasetti, K., Di Ninno, V., Schnell, G., Wong, J.P. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterisation and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother 1997, 41(6): 1288-92. (Pubitemid 27231428)
43. Bilton, D., DeSoyza, A., Haworth, C., Bruinenberg, P., Otulana, B. Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in non-CF bronchiectasis. Eur Respir J [19th Annu Congr Eur Respir Soc (ERS) (Sept 12-16, Vienna) 2009] 2009, 34(Suppl. 53), Abst 1362.
44. Chono, S., Tanino, T., Seki, T., Morimoto, K. Influence of particle size on drug delivery to rat alveolar macrophages following intrapulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target 2006, 14(8): 557-66. (Pubitemid 44592889)
45. Chono, S., Tanino, T., Seki, T., Morimoto, K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release 2008, 127(1): 50-8.
46. Adi, H., Young, P.M., Chan, H-K., Salama, R., Traini, D. Controlled release antibiotics for dry powder lung delivery. Drug Dev Ind Pharm 2010, 36(1): 119-26.
47. Sweeney, L.G., Wang, Z., Loebenberg, R., Wong, J.P., Lange, C.F., Finlay, W.H. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005, 305(1-2): 180-5. (Pubitemid 41568373)
48. Chono, S., Suzuki, H., Togami, K., Morimoto, K. Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for the treatment of respiratory infections. Drug Dev Ind Pharm 2011, 37(4): 367-82.
49. Moazeni, E., Gilani, K., Sotoudegan, F. et al. Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. J Microencaps 2010, 27(7): 618-27.
50. Adi, H., Young, P.M., Chan, H-K., Stewart, P., Agus, H., Traini, D. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci 2008, 97(8): 3356-66.
51. Adi, H., Young, P.M., Chan, H-K., Agus, H., Traini, D. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci 2010, 40(3): 239-47.
52. Yang, Y., Tsifansky, M.D., Wu, C-J., Yang, H.I., Schmidt, G., Yeo, Y. Inhalable antibiotic delivery using a dry powder codelivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm Res 2010, 27(1): 151-60.
53. Finlay, W.H., Wong, JP. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int J Pharm 1998, 167(1-2): 121-7. (Pubitemid 28341513)
54. Stass, H., Nagelschmitz, J., Weimann, B., Timmer, W. Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder for inhalation in patients with mild to moderate chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med [107th Int Conf Am Thorac Soc (May 13-18, Denver) 2011] 2011, 183(3): Abst 3730.
55. Tokimatsu, I., Hiramatsu, K., Morimoto, T. et al. Safety, tolerability, and pharmacokinetics of a single dose of ciprofloxacin dry powder for inhalation in Japanese patients with mild to moderate chronic obstructive pulmonary disease: a randomised controlled trial. Am J Respir Crit Care Med [107th Int Conf Am Thorac Soc (May 13-18, Denver) 2011] 2011, 183(3): Abst 3105.
56. Dorkin, H., Criollo, M., Reimnitz, P., Alder, J., Hampel, B. Randomized, double-blind, placebo-controlled, multicentre study to evaluate the safety and efficacy of inhaled ciprofloxacin compared with placebo in patients with cystic fibrosis - a phase IIb study of ciprofloxacin dry powder for inhalation (DPI). Pediatr Pulmonol [25th Annu North Am Cystic Fibrosis Conf (Nov 3-5, Anaheim) 2011] 2011, 46(S34): Abst 235.
57. Wilson, R., Welte, T., Polverino, E. et al. Randomized, placebo-controlled, double-blind, multi-center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo in patients with non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med [107th Int Conf Am Thorac Soc (May 13-18, Denver) 2011] 2011, 183(3): Abst 6407.
58. Bruinenberg, P., Wilson, J., Serisier, D., Otulana, B., Blanchard, J. Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients. Eur Respir J [19th Annu Congr Eur Respir Soc (ERS) (Sept 12-16, Vienna) 2009] 2009, 34(Suppl. 53), Abst 1625.
59. Bruinenberg, P., Serisier, D., Cipolla, D., Blanchard, J. Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers and non-cystic fibrosis bronchiectasis patients. Am J Respir Crit Care Med [106th Int Conf Am Thorac Soc (May 14-19, New Orleans) 2010] 2010, 181(Abstract Issue): Abst 3192.
60. Bruinenberg, P., Serisier, D., Blanchard, J., Cipolla, D., Gonda, I. Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. 20th Annu Congr Eur Respir Soc (ERS) (Sept 18-22, Barcelona) 2010, Abst 5574.
61. Bruinenberg, P., Otulana, B., Blanchard, J., Morishige, R., Cipolla, D., Wilson, J., Serisier, D. The effect of once-a-day liposomal inhaled ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization. Pediatr Pulmonol [22nd Annu North Am Cystic Fibrosis Conf (Oct 23-25, Orlando) 2008] 2008, 43(S31): Abst 401.
62. Bilton, D., Serisier, D.J., De Soyza, A., Wolfe, R., Bruinenberg, P. Multi-center, randomized, double-blind, placebo-controlled study (ORBIT-1) to evaluate the efficacy, safety, and tolerability of once-daily ciprofloxacin for inhalation in the management of Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis. Annu Congr Eur Respir Soc (ERS) (Sept 24-28, Amsterdam) 2011, Abst 1925.
63. Serisier, D.J., Kolbe, J., Bruinenberg, P., Gonda, I. Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa (PA) density and increases time to first exacerbation in a 168 day placebo-controlled study in non-cystic fibrosis bronchiectasis (non-CF BE). Am J Respir Crit Care Med [107th Int Conf Am Thorac Soc (May 13-18, Denver) 2011] 2011, 183(3): Abst 4866.
64. Lopez-Dupla, M., Martinez, J-A., Vidal, F. et al. Previous ciprofloxacin exposure is associated with resistance to β-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control 2009, 37(9): 753-8.
65. Didier, J.P., Villet, R., Huggler, E., Lew, D.P., Hooper, D.C., Kelley, W.L., Vaudaux, P. Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance. Antimicrob Agents Chemother 2011, 55(5): 1946-52.
66. Cohen, S.P., McMurray, L.M., Hooper, D.C., Wolfson, J.S., Levy, S.B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant Eschericia Coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicr Agents Chemother 1989, 33(8): 1318-25. (Pubitemid 19191979)
67. Fantin, B., Duval, X., Massias, L. et al. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis 2009, 200(3): 390-8.